Abstract
Colorectal cancer (CRC) is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been established. The epidermal growth factor receptor (EGFR) is overexpressed in the 80% of colorectal cancer and correlate with a poor prognosis. Cetuximab (C225, Erbitux TM) is chimeric human-mouse G1 immunoglobulin that binds to the EGFR with a 10-fold higher affinity than the natural ligands TGF?? and EGF. Cetuximab is currently licensed worldwide for the treatment of irinotecan-refractory metastatic CRC disease. It is well tolerated and the major adverse event is skin rash which also correlates with clinical response to treatment. An extensive phase II and III program of evaluation of cetuximab activity and efficacy in different settings of metastatic CRC has been undertaken. This article will review the current knowledge on the role of cetuximab in the medical management of metastatic CRC.
Keywords: Cetuximab, metastatic colorectal cancer, chimeric anti-EGFR monoclonal antibody
Current Cancer Therapy Reviews
Title: Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Volume: 3 Issue: 4
Author(s): Erika Martinelli, Michele Orditura, Ferdinando De Vita, Gennaro Galizia and Fortunato Ciardiello
Affiliation:
Keywords: Cetuximab, metastatic colorectal cancer, chimeric anti-EGFR monoclonal antibody
Abstract: Colorectal cancer (CRC) is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been established. The epidermal growth factor receptor (EGFR) is overexpressed in the 80% of colorectal cancer and correlate with a poor prognosis. Cetuximab (C225, Erbitux TM) is chimeric human-mouse G1 immunoglobulin that binds to the EGFR with a 10-fold higher affinity than the natural ligands TGF?? and EGF. Cetuximab is currently licensed worldwide for the treatment of irinotecan-refractory metastatic CRC disease. It is well tolerated and the major adverse event is skin rash which also correlates with clinical response to treatment. An extensive phase II and III program of evaluation of cetuximab activity and efficacy in different settings of metastatic CRC has been undertaken. This article will review the current knowledge on the role of cetuximab in the medical management of metastatic CRC.
Export Options
About this article
Cite this article as:
Martinelli Erika, Orditura Michele, Vita De Ferdinando, Galizia Gennaro and Ciardiello Fortunato, Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782497068
DOI https://dx.doi.org/10.2174/157339407782497068 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Gene Therapy for Gastrointestinal and Liver Cancers: Past Experience, Current Status and Future Perspectives)
Current Gene Therapy Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Molecular Docking Studies of Glycyrrhetinic Acid Derivatives as Anti- Colorectal Cancer Agents
Current Computer-Aided Drug Design Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy
Current Topics in Medicinal Chemistry Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Synthesis and Evaluation of Indole Based Molecules for Treatment of Oxidative Stress Related Diseases
Current Topics in Medicinal Chemistry Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Applications of Circadian Metabolomics
Current Metabolomics NSAIDs and Chemoprevention
Current Cancer Drug Targets microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Oxaliplatin for Colorectal Cancer Therapy: A Review
Clinical Cancer Drugs Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice
Current Genomics Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Analytic strategies to evaluate the association of time-varying exposures to HIV-related outcomes: Alcohol consumption as an example
Current HIV Research Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued)